��ժҪ��Ϣ

[an error occurred while processing this directive]

��Ƥ��Բ�ѧ��־ 2006, 32(6) 380-382 DOI: ISSN: 2096-5540 CN: 32-1880/R

��Ŀ¼ | ��Ŀ¼ | �� | �߼�� [��ӡ��ҳ] [�ر�]

��

	��չ��

	��Ϣ
	Supporting info
	PDFȫ��
	[HTMLȫ��]
	�ο��
	��뷴��
	�ѱ��Ƽ��
	��ҵ��
	��ù��
	��ñ��
	Email Alert
	��·��
	��Ϣ
	��Ĺؼ��
	��м��
	��ϸ��-10
	��
	Ȩ��
	��ɭ
	��ѧ��
	PubMed
	Article by QUAN Cheng
	Article by YANG Sen
	Article by ZHANG Xue-jun

�׽��-10��м��

Ȩ��, ��ɭ, ��ѧ��

��ҽ�ƴ�ѧƤ��о��һ��ҽԺƤ��, �Ϸ�230022

ժҪ��

��м��һ�ֳ��ĺ��м��Ƥ��,��ߵ��쳣��Ҫ��²��֮һ��׽��-10��һ�־��ж��ߵ��õ�Th2��ϸ��,�ܹ��ƽ��γ�ϸ��ֳ�ͷֻ�,�ٽ��ϸ��ģʽ��ת��,��м��Ƥ��Tϸ��ٴ��֤ʵ,IL-10��Ŀ��м��,��ض��,��ϣ��Ϊ��м��һ��ֶΡ�

�ؼ���� м�� ϸ��-10

Interleukin-10 and psoriasis

Institute of Dermatology of Anhui Medical University, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China

Abstract:

Psoriasis is a common chronic inflammatory skin disease, and immunoregulation abnormality is one of the important factors involved in its pathogenesis. Interleukin-10 is a pluripotent cytokine with major impacts on several immune responses, including inhibiting keratinocyte proliferation and differentiation, promoting type 1/type 2 cytokine balance shift, decreasing cutaneous T cell infiltration. The antipsoriatic activity of IL-10 has been demonstrated in clinical trials. And it could be a promising candidate for the treatment of psoriasis.

Keywords: Psoriasis Interleukin-10

�ո�� 2006-01-26 �޻�� ��淢��

DOI:

��Ŀ:

ͨѶ��: ��ѧ��,email:ayzxj@vip.sina.com

��߼��:

�ο��ף�

[1] Fiorentino DF,Bond MW,Mosmann TR.Two types of mouse T helper cell.IV.Th2 clones secrete a factor that inhibits cytokine production by Thl clones.J Exp Med,1989,170:2081-2095.
[2] Fickenscher H,Hor S,Kupers H,et al.The interleukin-10 family of cytokines.Trends Immunol,2002,23:89-96.
[3] Weiss E,Mamelak AJ,La Morgia S,et al.The role of interleukin 10 in the pathogenesis and potential treatment of skin diseases.J Am Acad Dermatol,2004,50:657-675; quiz 676-678.
[4] Asadullah K,Sterry W,Stephanek K,et al.IL-10 is a key cytokine in psoriasis.Proof of principle by IL-10 therapy:a new therapeutic approach.J Clin Invest,1998,101:783-794.
[5] Jacob SE,Nassiri M,Kerdel FA,et al.Simultaneous measurement of multiple Thl and Th2 serum cytokines in psoriasis and correlation with disease severity.Mediators Inflamm,2003,12:309-313.
[6] Kingo K,Ratsep R,Koks S,et al.Influence of genetic polymorphisms on interleukin-10 mRNA expression and psoriasis susceptibility.J Dermatol Sci,2005,37:111-113.
[7] Asadullah K,Eskdale J,Wiese A,et al.Interleukin-10 promoter polymorphism in psoriasis.J Invest Dermatol,2001,116:975-978.
[8] Hensen P,Asadullah K,Windemuth C,et al.Interleukin-10 promoter polymorphism IL10.G and familial early onset psoriasis.Br J Dermatol,2003,149:381-385.
[9] Kingo K,Koks S,Silm H,et al.IL-10 promoter polymorphisms influence disease severity and course in psoriasis.Genes Immun,2003,4:455-457.
[10] Asadullah K,Friedrich M,Hanneken S,et al.Effects of systemic interleukin-10 therapy on psoriatic skin lesions:histologic,immunohistologic,and molecular biology findings.J Invest Dermatol,2001,116:721-727.
[11] Reich K,Garbe C,Blaschke V,et al.Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation,downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation.J Invest Dermatol,2001,116:319-329.
[12] McInnes IB,Illei GG,Danning CL,et al.IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis.J Immunol,2001,167:4075-4082.
[13] Seifert M,Sterry W,Effenberger E,et al.The antipsoriatic activity of IL-10 is rather caused by effects on peripheral blood cells than by a direct effect on human keratinocytes.Arch Dermatol Res,2000,292:164-172.
[14] Seifert M,Gruenberg BH,Sabat R,et al.Keratinocyte unresponsiveness towards interleukin-10:lack of specific binding due to deficient IL-10 receptor 1 expression.Exp Dermatol,2003,12:137-144.
[15] Asadullah K,Docke WD,Ebeling M,et al.Interleukin 10 treatment of psoriasis:clinical results of a phase 2 trial.Arch Dermatol,1999,135:187-192.
[16] Friedrich M,Docke WD,Klein A,et al.Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in Psoriasis.J Invest Dermatol,2002,118:672-677.
[17] Kimball AB,Kawamura T,Tejura K,et al.Clinical and immunologic assessment of patients with psoriasis in a randomized,double-blind,placebo-controlled trial using recombinant human interleukin 10.Arch Dermatol,2002,138:1341-1346.